Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Asset 3 (Galapagos NV)
- Development stage
- Preclinical
- Lead developer
- Galapagos
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Asset 3 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy currently in the discovery phase, developed by Galapagos' CellPoint division. It is designed to target an undisclosed antigen for the treatment of solid tumors, specifically small-cell lung cancer (SCLC) and neuro-endocrine tumors (NETs). The program was part of Galapagos' portfolio utilizing a decentralized manufacturing platform intended to provide point-of-care CAR-T cell production. However, in October 2025, Galapagos announced plans to wind down the CellPoint division, leaving the future development status of this preclinical asset uncertain.
- Other names
- Galapagos (CellPoint division)-Non-disclosed-CAR-T cell therapy-Small-cell lung cancer-Neuro-endocrine tumors
Beyond the preview
Go deeper on Asset 3 (Galapagos NV).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asset 3 (Galapagos NV).